Prostate cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 12,657 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  High-resolution Intra-operative PSMA PET-CT in Prostate Cancer

  NCT06298838· IRCCS San Raffaele· Updated 6 Nov 2026

  “Difficulties in patient recruitment”Registry text, quoted unchanged. Source

• Suspended

  White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

  NCT04519879· City of Hope Medical Center· Updated 4 Nov 2026

  “05/26/2026 DSMC: Delinquent PMT reporting.”Registry text, quoted unchanged. Source

• Suspended

  Prostasomes as Diagnostic Tool for Prostate Cancer Detection

  NCT03694483· Hackensack Meridian Health· Updated 3 Nov 2026

  “Staffing changes, pending funding renewal”Registry text, quoted unchanged. Source

• Terminated

  Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT05425862· Peter MacCallum Cancer Centre, Australia· Updated 2 Nov 2026

  “It was decided to stop the study due to changes in the treatment landscape.”Registry text, quoted unchanged. Source

• Withdrawn

  Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT07090369· Peter MacCallum Cancer Centre, Australia· Updated 30 Oct 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Suspended

  Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

  NCT07219303· Fox Chase Cancer Center· Updated 29 Oct 2026

  “Pending interim analysis”Registry text, quoted unchanged. Source

• Withdrawn

  Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

  NCT07075705· Roswell Park Cancer Institute· Updated 29 Oct 2026

  “Not planning to pursue”Registry text, quoted unchanged. Source

• Withdrawn

  A Novel Augmented Reality System (ARssist) for the Assistant Surgeon in Robotic Assisted Surgery

  NCT04304079· Chinese University of Hong Kong· Updated 27 Oct 2026

  “No funding”Registry text, quoted unchanged. Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Swiss Cancer Institute· Updated 23 Oct 2026

  “Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication”Registry text, quoted unchanged. Source

• Terminated

  Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

  NCT05960578· University of Washington· Updated 19 Oct 2026

  “The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  NCT07902921· National Cancer Institute (NCI)· Source

• Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions

  NCT07391982· The Netherlands Cancer Institute· Source

• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

  NCT07667400· National Cancer Institute (NCI)· Source

• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07287150· Hoffmann-La Roche· Source

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

• Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

  NCT07574541· National Cancer Institute (NCI)· Source

• Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

  NCT01834001· National Cancer Institute (NCI)· Source

• The Vanguard Study: Testing a New Way to Screen for Cancer

  NCT06995898· National Cancer Institute (NCI)· Source

• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

  NCT06136624· Merck Sharp & Dohme LLC· Source

• Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

  NCT02594202· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 41
• Organoids 15
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 14
• Gene Expression Profiling 152
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 31
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 124
• Magnetic Resonance Imaging 460
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 274
• Genome-Wide Association Study 60

• Identification of ageing-related genes in prostate cancer with type 2 Diabetes using machine learning: a multi-omics study focusing on SOX4, PRNP, and FOXO4.

  Artif Cells Nanomed Biotechnol, Oct 2026

• Development and External Validation of a Machine Learning-Derived Risk Stratification Score for Metastatic Castration-Resistant Prostate Cancer.

  JCO Clin Cancer Inform, Oct 2026

• Potential Molecular Links Between Triclosan Exposure and Prostate Cancer: An Integrative Computational Analysis.

  Int J Mol Sci, Oct 2026

• Untranslated Region-FNex: An Integrative Multimodal Framework for Functional Untranslated Region Variant Prioritization.

  J Chem Inf Model, Oct 2026

• Interpretable Machine Learning Prognostic Model Integrating Inflammatory-Nutritional Biomarkers for Post-Prostatectomy Biochemical Recurrence: Development, Internal Validation, and Translational Target Exploration.

  Curr Oncol, Oct 2026

• Predicting miRNA-Disease Associations Based on Contrastive Learning of Linear and Nonlinear Features.

  Genes (Basel), Oct 2026

• Explainable Machine Learning-Based Prediction of Progression-Free Survival in Prostate Cancer: Retrospective Cohort Study.

  JMIR Cancer, Oct 2026

• General versus site specific quantile random forest models for virtual patient-specific quality assurance of VMAT plans.

  J Appl Clin Med Phys, Oct 2026

• Development and external validation of an explainable machine-learning model for early complications following robot-assisted radical prostatectomy: a multicenter study.

  J Robot Surg, Oct 2026

• Development and evaluation of a combined machine learning model for the prediction of acute GU toxicity in prostate cancer radiotherapy.

  Phys Med, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.